Substituted pyrroline kinase inhibitors

• US 7,786,135 B2
• Filed: 05/17/2006
• Issued: 08/31/2010
• Est. Priority Date: 05/08/2002
• Status: Expired due to Fees

• Current Assignee: Janssen Pharmaceutica NV (Johnson & Johnson)
• Original Assignee: Janssen Pharmaceutica NV (Johnson & Johnson)
• Inventors: O'Neill, David, Shen, Lan, Conway, Bruce R., Ye, Hong, Demarest, Keith, Maryanoff, Bruce E., Kuo, Gee-Hong, Zhang, Han-Cheng, McComsey, David F.
• Primary Examiner(s): Saeed; Kamal A
• Assistant Examiner(s): Shterengarts; Samantha L
• Application Number:
  US11/436,000
• Publication Number:
  US 20060205763A1
• Time in Patent Office: 1,567 Days
• Field of Search: 548/400, 548/416, 548/452, 548/454, 514/359, 514/408, 514/410, 514/412, 514/414, 514/300
• US Class Current: 514/300
• CPC Class Codes: A61P 11/06 Antiasthmatics
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 17/06 Antipsoriatics
• CPC Class Codes: A61P 17/14 for baldness or alopecia
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/04 Centrally acting analgesics, e.g. opioids
• CPC Class Codes: A61P 25/08 Antiepileptics; Anticonvulsants
• CPC Class Codes: A61P 25/18 Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• CPC Class Codes: A61P 25/24 Antidepressants
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 31/18 for HIV
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: A61P 39/00 General protective or antinoxious agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 7/02 Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• CPC Class Codes: A61P 7/10 : Antioedematous agents; Diuretics
• CPC Class Codes: A61P 9/00 : Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/04 : Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
• CPC Class Codes: A61P 9/10 : for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: A61P 9/12 : Antihypertensives
• CPC Class Codes: C07D 471/04 : Ortho-condensed systems

Abstract

The present invention is directed to novel substituted pyrroline compounds useful as kinase inhibitors and methods for treating or ameliorating a kinase mediated disorder.

Claims

1. A method for treating or ameliorating diabetes in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a compound of Formula (I):

2. The method of claim 1 wherein the disorder is mediated by selective inhibition of a kinase selected from the group consisting of protein kinase C and glycogen synthase kinase-3.

3. The method of claim 2 wherein the kinase is selected from the group consisting of protein kinase C β

-II and glycogen synthase kinase-3β

.

4. The method of claim 1 wherein the therapeutically effective amount of the compound of claim 1 is from about 0.001 mg/kg/day to about 300 mg/kg/day.

5. The method of claim 1 wherein diabetes is selected from the group consisting of insulin dependent diabetes and Type II non-insulin dependent Diabetes mellitus.

6. The method of claim 1 further comprising administering to a subject in need thereof a therapeutically effective amount of the compound of claim 1 with a pharmaceutically acceptable carrier.

7. The method of claim 6 wherein the therapeutically effective amount is from about 0.001 mg/kg/day to about 300 mg/kg/day.